Venetoclax (VTX), a BH3 mimetic, antagonist of BCL-2, has been approved for the treatment of chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and is undergoing clinical trials for the treatment of multiple myeloma (MM) [6–8]. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.